---
document_datetime: 2025-06-20 14:34:56
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/yorvipath-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: yorvipath-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.2983339
conversion_datetime: 2025-12-19 00:16:59.419928
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Yorvipath

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a group of | 23/05/2025                          | N/A                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000266683   | variations. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.4 Change to in-process tests or applied during the manufacture of the substance - B.I.a.4.z Other variation - Accepted B.I.a.4 Change to in-process tests or applied during the manufacture of the substance - B.I.a.4.z Other variation -   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| Variation type IA / EMA/VR/0000266673   | B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted                                                                                                                                                                                                                                                                                                                | 16/05/2025   | N/A   |             |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------|
| Variation type II / EMA/VR/0000247280   | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 5.3 of the SmPC in order to update preclinical safety information related to pre- and post-natal development based on the final results from a PPND study (study 9000926). This is a nonclinical study in rats. In addition, the MAH took the opportunity to introduce a correction to section 4.2 of the SmPC and to section 6 of the package leaflet. | 10/04/2025   |       | SmPC and PL |
| Variation type IB / EMA/VR/0000256152   | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the                                                                                                                                                                                                                                                                                                                                                                                                                                 | 27/03/2025   | N/A   |             |

<div style=\"page-break-after: always\"></div>

|                                          | manufacturing process of the active substance - B.I.b.2.z Other changes - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.z Other changes - Accepted   |            |     |                                                                                                                                                                                                                                                              |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000245400    | B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.z Other variation - Accepted                                            | 25/02/2025 | N/A |                                                                                                                                                                                                                                                              |
| Variation type IA_IN / EMA/VR/0000247283 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted        | 28/01/2025 |     |                                                                                                                                                                                                                                                              |
| PSUR / EMA/PSUR/0000248444               | - - n/a                                                                                                                                                                               |            |     | Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit balance of medicinal products containing palopegteriparatide remains unchanged and therefore recommends the maintenance of the marketing authorisation(s). |